{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:03Z","timestamp":1790186523037,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40123-026-01405-1","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:44:38Z","timestamp":1782924278000},"page":"2563-2586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in Polypoidal Choroidal Vasculopathy (PCV) Management: Emerging Evidence for Faricimab and Aflibercept 8\u00a0mg"],"prefix":"10.1007","volume":"15","author":[{"given":"Mohamed Zakaria","family":"Sherif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Y. C.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y. Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiok Hong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau J.","family":"Fenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"3","key":"1405_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/01.APO.0000656992.00746.48","volume":"9","author":"V Chaikitmongkol","year":"2020","unstructured":"Chaikitmongkol V, Cheung CMG, Koizumi H, Govindahar V, Chhablani J, Lai TYY. Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment. Asia Pac J Ophthalmol. 2020;9(3):260\u20138. https:\/\/doi.org\/10.1097\/01.APO.0000656992.00746.48.","journal-title":"Asia Pac J Ophthalmol"},{"issue":"2","key":"1405_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"1405_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1\u20138.","journal-title":"Retina"},{"issue":"5","key":"1405_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125(5):708\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.019.","journal-title":"Ophthalmology"},{"issue":"3","key":"1405_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2021;128(3):443\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.006.","journal-title":"Ophthalmology"},{"key":"1405_CR6","doi-asserted-by":"publisher","first-page":"251584141983115","DOI":"10.1177\/2515841419831152","volume":"11","author":"A Kumar","year":"2019","unstructured":"Kumar A, Kumawat D, Sundar MD, et al. Polypoidal choroidal vasculopathy: a comprehensive clinical update. Ther Adv Ophthalmol. 2019;11:2515841419831152. https:\/\/doi.org\/10.1177\/2515841419831152.","journal-title":"Ther Adv Ophthalmol"},{"issue":"1","key":"1405_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res. 2010;29(1):19\u201329. https:\/\/doi.org\/10.1016\/j.preteyeres.2009.10.001.","journal-title":"Prog Retin Eye Res"},{"key":"1405_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee WK, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107\u201339. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.04.002.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1405_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/11206721221100624","volume":"33","author":"R Venkatesh","year":"2023","unstructured":"Venkatesh R, Mishra P, Nahata H, Reddy NG, Yadav NK, Chhablani J. Peripheral and macular polypoidal choroidal vasculopathy: a retrospective comparative case series. Eur J Ophthalmol. 2023;33(1):448\u201354. https:\/\/doi.org\/10.1177\/11206721221100624.","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"1405_CR10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453\u201364. https:\/\/doi.org\/10.1097\/IAE.0b013e31824f91e8.","journal-title":"Retina"},{"issue":"7","key":"1405_CR11","first-page":"383","volume":"109","author":"T Iida","year":"2005","unstructured":"Iida T. Diagnostic criteria for polypoidal choroidal vasculopathy and their clinical significance. Nippon Ganka Gakkai Zasshi. 2005;109(7):383\u20134.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"5","key":"1405_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.iae.0000249386.63482.05","volume":"27","author":"T Sato","year":"2007","unstructured":"Sato T, Kishi S, Watanabe G, Matsumoto H, Mukai R. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina. 2007;27(5):589\u201394. https:\/\/doi.org\/10.1097\/01.iae.0000249386.63482.05.","journal-title":"Retina"},{"issue":"6","key":"1405_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaophthalmol.2019.0565","volume":"137","author":"V Chaikitmongkol","year":"2019","unstructured":"Chaikitmongkol V, Kong J, Khunsongkiet P, et al. Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy. JAMA Ophthalmol. 2019;137(6):661\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.0565.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1405_CR14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ajo.2014.08.025","volume":"158","author":"G De Salvo","year":"2014","unstructured":"De Salvo G, Vaz-Pereira S, Keane PA, Tufail A, Liew G. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 2014;158(6):1228-1238.e1. https:\/\/doi.org\/10.1016\/j.ajo.2014.08.025.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1405_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/bjophthalmol-2013-304658","volume":"99","author":"K Sayanagi","year":"2015","unstructured":"Sayanagi K, Gomi F, Akiba M, Sawa M, Hara C, Nishida K. En-face high-penetration optical coherence tomography imaging in polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99(1):29\u201335. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304658.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1405_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ophtha.2010.09.012","volume":"118","author":"SE Chung","year":"2011","unstructured":"Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology. 2011;118(5):840\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2010.09.012.","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"1405_CR17","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1097\/IAE.0000000000001346","volume":"36","author":"WK Lee","year":"2016","unstructured":"Lee WK, Baek J, Dansingani KK, Lee JH, Freund KB. Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina. 2016;36(Suppl 1):S73-82. https:\/\/doi.org\/10.1097\/IAE.0000000000001346.","journal-title":"Retina"},{"issue":"1","key":"1405_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-025-03715-y","volume":"45","author":"JPB Lacanilao","year":"2025","unstructured":"Lacanilao JPB, Artiaga JCM. Polypoidal choroidal vasculopathy features among Filipino eyes with neovascular AMD: application of the Asia Pacific Ocular Smaging Society non-ICGA criteria. Int Ophthalmol. 2025;45(1):351. https:\/\/doi.org\/10.1007\/s10792-025-03715-y.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"1405_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/APO.0000000000000602","volume":"12","author":"NV Radke","year":"2023","unstructured":"Radke NV, Mohamed S, Brown RB, et al. Review on the safety and efficacy of brolucizumab for neovascular age-related macular degeneration from major studies and real-world data. Asia Pac J Ophthalmol. 2023;12(2):168\u201383. https:\/\/doi.org\/10.1097\/APO.0000000000000602.","journal-title":"Asia Pac J Ophthalmol"},{"key":"1405_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong TY, Ogura Y, Lee WK, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol. 2019;204:80\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2019.02.027.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"1405_CR21","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206\u201313. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4030.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"1405_CR22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","volume":"38","author":"Y Yanagi","year":"2018","unstructured":"Yanagi Y, Ting DSW, Ng WY, et al. Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy. Retina Phila Pa. 2018;38(8):1509\u201317. https:\/\/doi.org\/10.1097\/IAE.0000000000001758.","journal-title":"Retina Phila Pa"},{"issue":"7","key":"1405_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786\u201393. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.1804.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"1405_CR24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37(3):1173\u201387. https:\/\/doi.org\/10.1007\/s12325-020-01236-x.","journal-title":"Adv Ther"},{"issue":"10432","key":"1405_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase\u00a03 trial. Lancet. 2024;403(10432):1141\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1.","journal-title":"Lancet"},{"issue":"9","key":"1405_CR26","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, et al. Effect of high-dose intravitreal aflibercept, 8\u00a0mg, in patients with neovascular age-related macular degeneration: the phase\u00a02 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141(9):834\u201342. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2421.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1405_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2026.100278","volume":"15","author":"A Chang","year":"2026","unstructured":"Chang A, Sun X, Iida T, et al. Intravitreal aflibercept 8\u00a0mg versus 2\u00a0mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the phase\u00a03 PULSAR trial. Asia-Pac J Ophthalmol. 2026;15(1):100278. https:\/\/doi.org\/10.1016\/j.apjo.2026.100278.","journal-title":"Asia-Pac J Ophthalmol"},{"key":"1405_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.5098","author":"WK Lee","year":"2025","unstructured":"Lee WK, Wong TY, Chen SJ, et al. Aflibercept 8\u00a0mg in polypoidal choroidal vasculopathy: post hoc analysis of the PULSAR randomized clinical trial. jAMA Ophthalmol. 2025. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.5098.","journal-title":"jAMA Ophthalmol"},{"issue":"12","key":"1405_CR29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.3390\/ph18121811","volume":"18","author":"Y Fukuda","year":"2025","unstructured":"Fukuda Y, Sakurada Y, Kotoda Y, Kimura M, Kashiwagi K. Comparison of three consecutive monthly administrations between aflibercept 8\u00a0mg and brolucizumab 6\u00a0mg in polypoidal choroidal vasculopathy. Pharmaceuticals. 2025;18(12):1811. https:\/\/doi.org\/10.3390\/ph18121811.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"1405_CR30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/ph18030438","volume":"18","author":"S Hosoda","year":"2025","unstructured":"Hosoda S, Sakurada Y, Fukuda Y, Kotoda Y, Kikushima W, Kashiwagi K. Short-term outcomes of three consecutive monthly loading administrations of aflibercept 8\u00a0mg for treatment-na\u00efve exudative age-related macular degeneration. Pharmaceuticals. 2025;18(3):438. https:\/\/doi.org\/10.3390\/ph18030438.","journal-title":"Pharmaceuticals"},{"key":"1405_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-026-01323-2","author":"CMG Cheung","year":"2026","unstructured":"Cheung CMG, Kikushima W, Teo KYC. Initial experiences of switching to aflibercept 8\u00a0mg for neovascular age-related macular degeneration and polypoidal chorodal vasculopathy in an Asian population. Ophthalmol Ther. 2026. https:\/\/doi.org\/10.1007\/s40123-026-01323-2.","journal-title":"Ophthalmol Ther"},{"issue":"7","key":"1405_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M. Faricimab: first approval. Drugs. 2022;82(7):825\u201330. https:\/\/doi.org\/10.1007\/s40265-022-01713-3.","journal-title":"Drugs"},{"issue":"8","key":"1405_CR33","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: two-year results from the phase\u00a03 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year\u00a02. Ophthalmology. 2024;131(8):914\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014.","journal-title":"Ophthalmology"},{"issue":"10326","key":"1405_CR34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16\u00a0weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase\u00a03, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"issue":"11","key":"1405_CR35","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00417-023-06071-8","volume":"261","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, Cheung CMG, Iida T, et al. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-year subgroup analysis of the TENAYA and LUCERNE trials. Graefes Arch Clin Exp Ophthalmol. 2023;261(11):3125\u201337. https:\/\/doi.org\/10.1007\/s00417-023-06071-8.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"1405_CR36","first-page":"1859","volume":"66","author":"J Lee","year":"2025","unstructured":"Lee J, Cheung G, Chen SJ, Iida T, Koh AHC, Lee WK, Ruamviboonsuk P, Sun X, Yanagi Y, Bai R, Margaron P (2025) Faricimab for polypoidal choroidal vasculopathy: week 16 results from the phase 3b\/4 SALWEEN trial. Invest Ophthalmol Vis Sci. 66(8):1859","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"1405_CR37","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.2147\/OPTH.S527787","volume":"19","author":"KCS Fong","year":"2025","unstructured":"Fong KCS, Wong WJJ, Wong HS, Ling KP, Fong SN, Shunmugam M. Switching to faricimab for polypoidal choroidal vasculopathy with real-world outcomes in refractory cases\u2014the FAR-PEARL study report 1. Clin Ophthalmol Auckl NZ. 2025;19:2475\u201385. https:\/\/doi.org\/10.2147\/OPTH.S527787.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"1405_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/OPTH.S448507","volume":"18","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Hata M, Tsuchikawa M, et al. Short-term outcomes of 3\u00a0monthly intravitreal faricimab on different subtypes of neovascular age-related macular degeneration. Clin Ophthalmol Auckl NZ. 2024;18:507\u201316. https:\/\/doi.org\/10.2147\/OPTH.S448507.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"1405_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251352888","volume":"9","author":"K Okawa","year":"2025","unstructured":"Okawa K, Maruyama-Inoue M, Chin JY, Inoue T, Yanagi Y, Kadonosono K. One-year outcomes of intravitreal faricimab injection in treatment-na\u00efve patients with neovascular age-related macular degeneration. J Vitreoretin Dis. 2025;9:24741264251352888. https:\/\/doi.org\/10.1177\/24741264251352888.","journal-title":"J Vitreoretin Dis"},{"key":"1405_CR40","doi-asserted-by":"publisher","first-page":"1346322","DOI":"10.3389\/fopht.2023.1346322","volume":"3","author":"FNI Ibrahim","year":"2023","unstructured":"Ibrahim FNI, Teo KYC, Tan TE, et al. Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. Front Ophthalmol. 2023;3:1346322. https:\/\/doi.org\/10.3389\/fopht.2023.1346322.","journal-title":"Front Ophthalmol"},{"issue":"3","key":"1405_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/aos.16797","volume":"103","author":"A Arnold-Vangsted","year":"2025","unstructured":"Arnold-Vangsted A, Schou MG, Balaratnasingam C, et al. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Acta Ophthalmol (Copenh). 2025;103(3):247\u201356. https:\/\/doi.org\/10.1111\/aos.16797.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"1405_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2024.1509065","volume":"4","author":"N Gilead","year":"2024","unstructured":"Gilead N, Chong YJ, Ibrahim FNI, Sun C, Teo KYC, Cheung CMG. Unexpected retinal fluid compartment responses with anti-VEGF therapy in polypoidal choroidal vasculopathy: a case report of four patients. Front Ophthalmol. 2024;4:1509065. https:\/\/doi.org\/10.3389\/fopht.2024.1509065.","journal-title":"Front Ophthalmol"},{"issue":"12","key":"1405_CR43","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1007\/s40123-025-01252-6","volume":"14","author":"A Tillmann","year":"2025","unstructured":"Tillmann A, Stillenmunkes R, Garweg JG, et al. One-year outcomes of faricimab in treatment-na\u00efve neovascular age-related macular degeneration: a Swiss Retina Research Network report. Ophthalmol Ther. 2025;14(12):3079\u201391. https:\/\/doi.org\/10.1007\/s40123-025-01252-6.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1405_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JCMA.0000000000001320","volume":"89","author":"CC Yang","year":"2026","unstructured":"Yang CC, Weng CC, Chou YB, et al. Early anatomical outcomes of faricimab vs aflibercept 2\u2009mg in treatment-na\u00efve neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: a head-to-head comparative study in Taiwan. J Chin Med Assoc. 2026;89(1):54\u201360. https:\/\/doi.org\/10.1097\/JCMA.0000000000001320.","journal-title":"J Chin Med Assoc"},{"issue":"16","key":"1405_CR45","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1038\/s41433-025-03980-2","volume":"39","author":"J Cho","year":"2025","unstructured":"Cho J, Han HY, Park S, Kim JH, Cho HJ. One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy: a comparative study. Eye. 2025;39(16):2893\u20138. https:\/\/doi.org\/10.1038\/s41433-025-03980-2.","journal-title":"Eye"},{"issue":"6","key":"1405_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060687","volume":"17","author":"M Kimura","year":"2024","unstructured":"Kimura M, Sakurada Y, Fukuda Y, et al. Association of polyp regression after loading phase with 12-month outcomes of eyes with polypoidal choroidal vasculopathy. Pharmaceuticals. 2024;17(6):687. https:\/\/doi.org\/10.3390\/ph17060687.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"1405_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2025.100176","volume":"14","author":"V Chaikitmongkol","year":"2025","unstructured":"Chaikitmongkol V, Tadadoltip W, Patikulsila D, et al. Recurrent polypoidal lesions after achieving inactive polypoidal choroidal vasculopathy following 1-year fixed-dosing aflibercept treatments. Asia-Pac J Ophthalmol. 2025;14(2):100176. https:\/\/doi.org\/10.1016\/j.apjo.2025.100176.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"1","key":"1405_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, et al. One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14(1):11681. https:\/\/doi.org\/10.1038\/s41598-024-62559-1.","journal-title":"Sci Rep"},{"issue":"7","key":"1405_CR49","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41433-025-03750-0","volume":"39","author":"V Chaikitmongkol","year":"2025","unstructured":"Chaikitmongkol V, Chatromyen P, Choovuthayakorn J, et al. Correlation between complete polypoidal regression and visual outcomes in polypoidal choroidal vasculopathy eyes receiving intravitreal aflibercept. Eye. 2025;39(7):1428\u201330. https:\/\/doi.org\/10.1038\/s41433-025-03750-0.","journal-title":"Eye"},{"issue":"5","key":"1405_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125150","volume":"10","author":"M Zhao","year":"2015","unstructured":"Zhao M, Bai Y, Xie W, et al. Interleukin-1\u03b2 level is increased in vitreous of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). PLoS ONE. 2015;10(5):e0125150. https:\/\/doi.org\/10.1371\/journal.pone.0125150.","journal-title":"PLoS ONE"},{"issue":"6","key":"1405_CR51","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/APO.0000000000000577","volume":"11","author":"H Zhou","year":"2022","unstructured":"Zhou H, Zhao X, Chen Y. Plasma cytokine profiles in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Asia-Pac J Ophthalmol. 2022;11(6):536\u201342. https:\/\/doi.org\/10.1097\/APO.0000000000000577.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"3","key":"1405_CR52","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","volume":"141","author":"JP Tong","year":"2006","unstructured":"Tong JP, Chan WM, Liu DTL, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456\u201362. https:\/\/doi.org\/10.1016\/j.ajo.2005.10.012.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1405_CR53","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1167\/iovs.11-7913","volume":"53","author":"S Sasaki","year":"2012","unstructured":"Sasaki S, Miyazaki D, Miyake K, et al. Associations of IL-23 with polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2012;53(7):3424\u201330. https:\/\/doi.org\/10.1167\/iovs.11-7913.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1405_CR54","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000548709","volume":"68","author":"C Zhang","year":"2025","unstructured":"Zhang C, Zhang W, Wang T, Wen L, Zhang J. Polypoidal choroidal vasculopathy: from clinicopathological and molecular perspectives. Ophthalmic Res. 2025;68(1):521\u201330. https:\/\/doi.org\/10.1159\/000548709.","journal-title":"Ophthalmic Res"},{"issue":"8","key":"1405_CR55","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1097\/IAE.0000000000000499","volume":"35","author":"CW Wong","year":"2015","unstructured":"Wong CW, Cheung CMG, Mathur R, et al. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review. Retina Phila Pa. 2015;35(8):1577\u201393. https:\/\/doi.org\/10.1097\/IAE.0000000000000499.","journal-title":"Retina Phila Pa"},{"key":"1405_CR56","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","volume":"37","author":"P Nowak-Sliwinska","year":"2013","unstructured":"Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AHC. Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res. 2013;37:182\u201399. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.09.003.","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"1405_CR57","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/bjo.2007.132357","volume":"92","author":"T Wakabayashi","year":"2008","unstructured":"Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol. 2008;92(7):936\u201340. https:\/\/doi.org\/10.1136\/bjo.2007.132357.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1405_CR58","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3928\/15428877-20090430-14","volume":"40","author":"SW Kim","year":"2009","unstructured":"Kim SW, Oh J, Oh IK, Huh K. Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2009;40(3):300\u20133. https:\/\/doi.org\/10.3928\/15428877-20090430-14.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"9","key":"1405_CR59","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST\u00a0II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935\u201342. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2443.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"1405_CR60","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40123-024-00888-0","volume":"13","author":"KYC Teo","year":"2024","unstructured":"Teo KYC, Park KH, Ngah NF, et al. Six-year outcomes in subjects with polypoidal choroidal vasculopathy in the EVEREST\u00a0II study. Ophthalmol Ther. 2024;13(4):935\u201354. https:\/\/doi.org\/10.1007\/s40123-024-00888-0.","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"1405_CR61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/ceo.14191","volume":"51","author":"MJ Sirks","year":"2023","unstructured":"Sirks MJ, Feenstra HMA, de Vries FR, Dijkman G, Boon CJF, van Dijk EHC. Argon laser photocoagulation in polypoidal choroidal vasculopathy. Clin Experiment Ophthalmol. 2023;51(2):177\u20139. https:\/\/doi.org\/10.1111\/ceo.14191.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"1","key":"1405_CR62","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase\u00a03, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017.","journal-title":"Ophthalmology"},{"issue":"7","key":"1405_CR63","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","volume":"106","author":"Y Ogura","year":"2022","unstructured":"Ogura Y, Jaffe GJ, Cheung CMG, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022;106(7):994\u20139. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319090.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1405_CR64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000521071","volume":"245","author":"D Montorio","year":"2022","unstructured":"Montorio D, Giordano M, Concilio M, Cennamo G. Structural and vascular changes of the choroid in polypoidal choroidal vasculopathy after intravitreal anti-VEGF therapy. Ophthalmologica. 2022;245(2):173\u20138. https:\/\/doi.org\/10.1159\/000521071.","journal-title":"Ophthalmologica"},{"issue":"15","key":"1405_CR65","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.15.5","volume":"62","author":"M Shen","year":"2021","unstructured":"Shen M, Zhou H, Kim K, et al. Choroidal changes in eyes with polypoidal choroidal vasculopathy after anti-VEGF therapy imaged with swept-source OCT angiography. Invest Ophthalmol Vis Sci. 2021;62(15):5. https:\/\/doi.org\/10.1167\/iovs.62.15.5.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3\u20134","key":"1405_CR66","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000533529","volume":"246","author":"A Mihalache","year":"2023","unstructured":"Mihalache A, Hatamnejad A, Patil NS, et al. Anti-vascular endothelial growth factor therapy regimens for polypoidal choroidal vasculopathy: a systematic review. Ophthalmologica. 2023;246(3\u20134):245\u201354. https:\/\/doi.org\/10.1159\/000533529.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1405_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2025.100144","volume":"14","author":"P Ruamviboonsuk","year":"2025","unstructured":"Ruamviboonsuk P, Ng DSC, Chaikitmongkol V, et al. Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS). Asia Pac J Ophthalmol. 2025;14(1):100144. https:\/\/doi.org\/10.1016\/j.apjo.2025.100144.","journal-title":"Asia Pac J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01405-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01405-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01405-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:04:26Z","timestamp":1785463466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01405-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1405"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01405-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mohamed Zakaria Sherif, Kelvin YC Teo, Timothy YY Lai, Hiok Hong Chan, Beau J. Fenner, and Won Ki Lee have nothing to disclose. Chui Ming Gemmy Cheung is an Editorial Board member of\u00a0\n                      Ophthalmology and Therapy\n                      . Chui Ming Gemmy Cheung was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}